{"id":"NCT04565990","sponsor":"Actelion","briefTitle":"A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study","officialTitle":"A Multicenter, Single-arm, Open-label, Long-term Follow-up Safety Study of Selexipag in Participants Who Participated in a Previous Selexipag Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-03","primaryCompletion":"2023-11-10","completion":"2023-11-10","firstPosted":"2020-09-28","resultsPosted":"2024-11-20","lastUpdate":"2025-05-01"},"enrollment":43,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension, Pulmonary"],"interventions":[{"type":"DRUG","name":"Selexipag","otherNames":["JNJ-67896049","ACT-293987"]}],"arms":[{"label":"Selexipag","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications for which a positive benefit-risk has been established.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)","effectByArm":[{"arm":"Selexipag","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":13,"countries":["Belarus","India","Romania","South Korea","Taiwan","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":43},"commonTop":["Covid-19","Chronic Gastritis","Pyrexia","Respiratory Tract Infection","Anaemia"]}}